Target intelligence / Profile preview

Homer scaffold protein 2 (HOMER2)

Target
HOMER2
Molecular classification
Other (postsynaptic density scaffolding protein, synaptic adaptor protein)
01

Overview

Homer scaffold protein 2 (HOMER2) is a postsynaptic density scaffolding/adaptor protein widely expressed in the central nervous system and other tissues, including the inner ear, skeletal muscle, heart, and others. It regulates synaptic signaling by physically linking and cross-linking various partner proteins—principally group 1 metabotropic glutamate receptors (mGluR1/GRM1, mGluR5/GRM5), inositol trisphosphate receptors (ITPR1), ryanodine receptors (RYR1/2), SHANK proteins, and elements involved in calcium signaling and cytoskeleton organization. HOMER2 enables dynamic regulation of synaptic plasticity, calcium signaling, and actin cytoskeletal structure, especially in glutamatergic synapses and sensory hair cells. Pathogenic variants in HOMER2 are causatively linked to autosomal dominant non-syndromic sensorineural hearing loss (DFNA68), and functional disruption leads to progressive hearing impairment. The protein contains an EVH1 domain for recognizing proline-rich target sequences and a coiled-coil domain facilitating multimerization and protein–protein interactions. HOMER2 is not a classical receptor, enzyme, transporter, or druggable target by conventional pharmacological standards, and there are no reported drugs that act directly on it.

Other names
Homer protein homolog 2Homer-2CupidinVesl-2HOMER-2BHOMER-2ADFNA68ACPDCPDVESL-2homer protein homolog 2cupidinhomer homolog 2homer homolog 3homer scaffolding protein 2neuronal immediate early gene 2
02

Biological functions

Synaptic receptor adaptor activityActin bindingProtein homodimerizationRegulation of group 1 metabotropic glutamate receptors (mGluRs)Regulation of intracellular calcium homeostasisOrganization of cytoskeletonSignal transduction at excitatory synapses
03

Disease associations

Neurodegenerative disease (notably, hereditary deafness—autosomal dominant non-syndromic sensorineural hearing loss/DFNA68)Possibly other neurological disorders, but the main association is with hearing loss
04

Safety considerations

Mutations in HOMER2 can cause progressive hereditary hearing loss (ADNSHL/DFNA68), with data suggesting a dominant-negative disease mechanism when certain sequence alterations are present. No other direct therapeutic safety concerns are widely reported.

Beyond the preview

Go deeper on Homer scaffold protein 2 (HOMER2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Homer scaffold protein 2 (HOMER2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call